The company reported ₤50.5 million for the year ended Sept. 30, 2012, up just slightly from the ₤49.7 million reported for the previous year. The company includes an Invibio biomaterial solutions business line.
More Articles on Orthopedic Devices:
13 Spine Devices Receive FDA 510(k) Clearance in September
How A Facility Implements Generic Orthopedic Implants
Pinnacle Spine Group Wins FDA Approval for Direct Lateral System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
